tbuckley/cabot-search huggingface dataset:
Retrieval-augmented large language models for clinical trial screening.
Authors: Ryan Tan, Si Xian Ho, Shiyun Vivianna Fequira Oo, Shi Ling Chua, Ma Wai Wai Zaw, Daniel Shao-Weng Tan
Journal: Journal of Clinical Oncology (2024)

e13611 Background: Clinical trial screening is currently manual and laborious. We tested several large language models enhanced with retrieval-augmented generation (RAG-LLM) to assess their performance on this task. Methods: We extracted eligibility criteria of 184 oncology trials with FDA approval notifications between 8 January 2020 and 18 January 2024, as well as information on cancer staging and performance status scoring for the RAG-LLM vector database. A medical oncologist and 2 senior clinical trial coordinators developed a test set of 975 synthetic patient profiles which included primary site, stage, prior therapy, tumor mutations and one additional clinical feature. Each profile was paired with one of the 184 trials and annotated for ground-truth eligibility and the reason for it. This process was repeated for another validation set of 240 longer and more challenging profiles paired with 8 ongoing trials. We developed RAG-LLMs with 4 leading LLMs (Zephyr-7B, Med42, GPT 3.5, GPT4) and evaluated their accuracy in determining trial eligibility as well as retrieval-augmented generation assessment (RAGAs) metrics. A response was deemed accurate only if it correctly assigned both trial eligibility and the reason for assignment. Results: GPT4 performed best and achieved an accuracy of 95.18% and 80.00% on the test and validation set respectively with a mean inference time of 10.95 seconds. It also demonstrated the highest answer relevancy, context relevancy and faithfulness (Table). Conclusions: Our results demonstrate potential for RAG-LLMs to assist with trial screening at scale. Further evaluation in real-world cohorts utilizing electronic records and full protocol data with tracking of impact on trial enrolment can be explored within secure firewalls. [Table: see text]
Trends in location of death for individuals with pediatric cancer in the United States.
Authors: Urvish Jain, Angelin Mathew, Bhav Jain, Erin Jay Garbes Feliciano, Edward Christopher Christopher Dee, Suzanne L. Wolden
Journal: Journal of Clinical Oncology (2024)

1591 Background: Children and adolescents with cancer face unique symptomatic, psychosocial, and existential challenges at the end of life (EOL). Premature death alongside severe pain and complex symptoms is distressing for the patients and families. Location of death is an important clinical and psychosocial decision for many patients. Therefore, we explored differences in location of death amongst pediatric patients with cancer using a large, national US database. Methods: We performed multinomial logistic regressions and analyzed trends in place of death for children and adolescents (ages 0 to 19) diagnosed with cancer from 2003-2019 using the Centers for Disease Control and Prevention Wide-Range Online Data for Epidemiologic Research database (CDC WONDER). We studied associations in place of death with essential decedent characteristics (age, sex, and race) for ICD10 codes C00-C96 and D00-D49, which encompass the most common causes of cancer death in children and adolescents. Results: Of 1,910 pediatric oncology decedents, 910 died in a hospital, 794 died at home, 12 died in nursing facilities, 59 in hospice, and 135 in outpatient facilities. Over time, death at home decreased by 50%. Death in the hospital increased by 64% and death in hospice increased by 200%. Children 10-19 years-of-age were more likely to die in hospice than children younger than 4 and children between 5-9 years-of-age. Additionally, they were less likely to die in outpatient medical facilities and ED. 1,388 decedents were White, 411 were Black, 18 were American Indian, and 93 were Asian. Children of racial and ethnic minorities were significantly more likely to die in hospitals than White children with cancer (Black: 1.81 [1.44-2.28], Asian: 1.57 [1.03-2.41], and Hispanic: 1.60 [1.26-2.04]). Black children with cancer were also more likely (1.67 [1.11-2.53]) to die in outpatient facilities compared to White children. Asian children &amp; Black children were less likely to die at home (0.48[0.38-0.61] and 0.55 [0.35-0.86] respectively). Conclusions: In contrast to the adult population that has demonstrated steady increases in deaths at home, for children with cancer, relative rates of death at home decreased while death in the hospital increased, with distinct differences among race/ethnic groups. Adequate education and support are needed to facilitate both autonomy and symptom palliation at EOL. Future work must explore underlying reasons for differences in place of death across time and demographic groups, so as to identify and alleviate any potential barriers, and to promote equitable access to a good death for each individual.
Improving access to infusion services: Results of an operational sprint.
Authors: Michelle Wilson, Paula Fonte-Smith, Jonathan Kalish, Alexander George, Dina Bernie Dumercy McHenry, Maria Suarez, Vicki Caraway, Mark Davis
Journal: Journal of Clinical Oncology (2024)

e13522 Background: As a large clinical academic cancer center growing from 40,772 unique patients in 2021 to 44,416 patients in 2022, access for patients to begin therapy in the infusion suite was delayed by 3.2 days. In addition to delays in care the center experienced decreased patient satisfaction related to timeliness of scheduling and an inflexible scheduling template that did not allow for the maximization of chair assets. An infusion sprint was launched to address the challenges with the main goal of providing a seamless patient experience while ensuring that all 60 chair assets were maximally utilized. The multi-disciplinary team sought to accomplish this through a disciplined evaluation and intervention program with the goals of increasing access, improving patient satisfaction and growing operating income. Methods: In February 2022, a multi-disciplinary team was assembled to develop and implement a plan to increase access to the infusion suite over a period of 6 months. The team utilized LEAN-Six Sigma principles to characterize current state, desired future state and tactical interventions with metrics. Access data, available infusion appointments and activities occurring in chairs were analyzed with the goal of maximizing utilization. This was accomplished through the development of an active asset management methodology that compared available infusion appointment hours in the schedule to the actual completed hours which allowed the center to determine the growth opportunity within the current chair count. Financial performance was reviewed, and a pilot of an AI-based scheduling platform was launched. Results: Data collected in December 2022 showed that the pilot increased average daily chemotherapy infusion patient volume by 10% and overall volume by 11% over prior fiscal year from October 2021 to September 2022. Daily scheduling escalations manually resolved by leadership decreased 54% between May 2022 and September 2022. Newly created chair utilization methodology showed increased utilization from 62% to 82% in 7 months and patient satisfaction increased from 76.97% to 81.18% for “Timeliness of Scheduling.” These initiatives also resulted in an 18% increase in infusion/pharmacy income from operations from October 2021 to September 2022. All of this was accomplished without adding staff to the workforce or chairs to the infusion suite. Conclusions: A focused, intentional, multi-disciplinary infusion sprint conducted over 6 months resulted in increases of patient access, increased patient satisfaction and revenue. External validity is limited by its one site design with future investigation planned at other sites within the cancer care network to determine if results can be reproduced.
Visualizing veterans’ care: Understanding the breadth of older veterans’ paid and family support network and implications for cancer care in the older adult population.
Authors: Imran Yousuf Ali, Nicholas Koufacos, Emily Franzosa, Lauren Hall
Journal: Journal of Clinical Oncology (2024)

e13777 Background: Many older adults rely on a complex network of paid and unpaid caregivers to age safely at home. Strong social networks have been long associated with improved cancer treatment outcomes in older adults. Yet medical records often only capture a primary family caregiver, and assessing support networks has not been a routine part of the equation in cancer treatment planning. We tested a novel visual tool, care mapping, with older veterans to better understand the scope of their caregiving networks. Methods: We created collaborative care maps with 10 dyads/triads of veterans and their primary paid and family caregivers receiving care at a large, urban, Veterans Health Administration medical center. Veterans were age 65+ and eligible for VA-paid home care. 50% of the veteran cohort had a cancer diagnosis. We compared the maps to veterans’ electronic medical records (EMRs) and assessed care network structure, function and adequacy. Results: For most veterans, care maps identified a larger number of care partners than EMRs alone. Functional, medical, socioemotional and spiritual supports included family, paid aides, neighbors, veteran service organizations and community groups. Unmet needs included inadequate home health workers to assist with functional decline associated with malignancy diagnosis. Veterans and caregivers largely described their networks as adequate, but mapping conversations surfaced a need for contingency care plans to relieve caregiver strain or if a caregiver could no longer provide support. Conclusions: Cancer care in older adults requires a broad, comprehensive approach and innovative ways to identify caregiver support. Such collaborative care maps can impact clinical outcomes by ensuring treatment adherence and symptom surveillance.
Evaluating the utility of routine survivorship exams in breast cancer: Modality of detection of recurrence in a prospective cohort study.
Authors: Ali Duffens, Cecile Laurent, Janise M. Roh, Lawrence H. Kushi, Raymond Liu
Journal: Journal of Clinical Oncology (2024)

1629 Background: National Comprehensive Cancer Network surveillance guidelines for invasive breast cancer recommend a history and physical exam every 3-12 months for the first 5 years, followed by annually, and mammography every 12 months. However, frequent in-office visits create time toxicity for breast cancer survivors, may have low utility in recurrence detection, and can create false reassurance. This study evaluates the modality of breast cancer recurrence in an integrated health system with access to primary and specialty care. Methods: We investigated mode of detection of recurrent breast cancer in the Pathways Study, a prospective cohort study of adult women diagnosed with and treated for invasive breast cancer in Kaiser Permanente Northern California, with enrollment from 2006 to 2013, and follow-up through December 2021. In this analysis, we included 4,431 women diagnosed at Stages I-III. Cohort members were followed for recurrences, deaths, and other outcomes. Of primary interest was modality of detection of recurrence, categorized as patient-driven symptoms, surveillance mammogram, diagnostic testing (i.e., other surveillance imaging for recurrence such as PET CT or MRI), routine clinical breast exam, or incidental finding. Results: A total of 617 (13.9%) women were identified as having breast cancer recurrence. Patients with recurrence shared similar demographic characteristics to those without recurrence. The recurrence population had median age of 59.2 years, BMI of 28.2 kg/m 2 , and racial/ethnic composition of 63% white,13% Hispanic,12% Asian, and 10% black. The median time from diagnosis to recurrence was 4 years. Seventy percent of recurrences were found to have distant metastatic disease, of which only 6.7% had concurrent local nodal and/or breast involvement. For those without metastases, 17.7% had recurrence localized in the ipsilateral breast, 2.8% in both the breast and locoregional nodes, and 9.3% only in locoregional nodes. Most recurrences were detected by patient driven symptoms (69.4%). Among the total cases, 8.1% of patients were diagnosed by routine mammogram, 10.9% with diagnostic testing and 4.5% by incidental finding. Recurrences in 6.8% of patients were detected by routine physician exam. Overall survival for those with recurrence was 31.1% and most deaths were attributed to breast cancer (89%). Conclusions: Our study, the largest investigation of breast cancer recurrence modality of detection in a US community oncology setting with comprehensive care, revealed the majority of recurrences were identified through patient self-detection with only 6.8% detected by physician exam. Most recurrences were distant, underscoring the need for alternative screening modalities to detect metastatic recurrences earlier, especially in the context of emerging treatments and improved survival rates for oligometastatic disease.
Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan.
Authors: Vivek Podder, Tulika Ranjan, Mainak Bardhan, Andrea McCracken, Charlie Hurmiz, Mohammad Arfat Ganiyani, Shahzaib Ahmad, Reshma L. Mahtani, Manmeet Singh Ahluwalia
Journal: Journal of Clinical Oncology (2024)

1036 Background: Breast cancer outcomes vary among HER2-amplified and HER2 low-expression patients, particularly in the presence of brain metastases (BM). Trastuzumab deruxtecan (T-DXd) is FDA approved for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low and HER2-positive (HER2+) patients (pts). This study aims to evaluate the impact of T-DXd treatment on overall survival among HER2 low and HER2-positive metastatic breast cancer (MBC) patients with and without brain metastases (BM). Methods: A retrospective analysis was conducted by using de-identified data available from seven US-based health systems part of Guardian Research Network (GRN). Patients treated with T-DXd from December 2019 to December 2023 with a diagnosis of HER2 low (immunohistochemistry [IHC] 1 + or IHC 2+/negative with HER2 FISH non-amplified) and HER2+ (IHC 3+ or HER2+ and FISH amplified MBC were included. Median overall survival (mOS), calculated from the initiation of T-DXd treatment, was assessed using Kaplan-Meier Curve analysis and Log-rank test. Results: A total of 380 MBC pts were identified. Among these 231 (61.1%) were stratified as having HER2 low and 149 (38.9%) HER2+ MBC. Pts with HER2+ disease had a higher prevalence of BM (n=70; 47%) compared to HER2-low pts (n=55;23.8%). The median age at BM diagnosis was 60.5 years, range: 21.6 to 87.1 years. Within the entire BM group (n=125), there were more pts with ER+ disease (81.9%) in the HER2 low group compared to HER2+ group (55.8%, p=0.01). The majority of these patients had multiple prior lines of therapy. HER2+ BM pts had a median overall survival (mOS) of 9.3 months [CI: 6.79-11.88, log rank p &lt;0.001], compared to 4.3 months [CI: 1.89-6.82, log rank p &lt;0.001] in the HER2-low pts. Without BM, HER2+ pts had a mOS of 10.7 months [CI: 0.71-20.82, log rank p &lt;0.001], compared to 6 months [CI: 3.47-8.67, log rank p &lt;0.001] in the HER2-low pts. Conclusions: In this retrospective study of heavily pretreated MBC patients with multiple prior lines of therapy, pts with HER2+ MBC with and without BM had a longer mOS compared to those with HER2- low disease, suggesting HER2 expression as a key determinant of T-DXd efficacy. Poor survival in MBC patients without BM was attributed to pre-treatment with multiple lines of therapy. Future research should explore combination therapies and predictive biomarkers while conducting clinical trials to optimize treatment strategies for HER2+ metastatic breast cancer patients.
Utilization and trends of BRAF and MEK inhibitors among Medicare D patients: 2013-2021.
Authors: Shanawar Ali Waris, Nanda Siva, Rahul Raiker, Adnan Saifuddin, Haig Pakhchanian, Gary Monroe, Salah Ud Din Safi
Journal: Journal of Clinical Oncology (2024)

e13581 Background: BRAF and MEK Inhibitors are selective anti-cancer medications that induce programmed cell death by targeting the BRAF/MEK pathway. BRAF and MEK were first approved in 2011 and 2013 respectively for the treatment of BRAF-mutated melanoma that include the V600E or V600K melanoma mutants. As additional BRAF/MEK inhibitors were introduced, scant data exists on national prescribing patterns and the goal was to examine this. Methods: A retrospective analysis was conducted using the Medicare Part D Prescriber datasets from 2013-2021. Data from BRAF (vemurafenib, dabrafenib, encorafenib) and MEK Inhibitors (trametinib, cobimetinib, binimetinib) prescriptions made by any healthcare providers were analyzed. Yearly claims per 100,000 beneficiaries, total drug costs, and total drug supply days were recorded. Compounded annual growth rate (CAGR) was calculated. Results: From 2013-2021, there was an 911% increase in the number of BRAF/MEK prescribers to Medicare Part D enrollees who made ≥11 claims. Majority of the prescribers were hematologists/oncologists. The highest proportion of claims and beneficiaries receiving BRAF/MEK inhibitors each year were those &gt;65 years of age and located in the South. An increased CAGR was seen for yearly claims per 100,000 beneficiaries (CAGR=31%), total drug costs (CAGR=40%), and total drug supply days (CAGR=36%). Conclusions: BRAF/MEK Inhibitor use has seen significant growth across all healthcare providers in claims made per 100k beneficiaries, total drug costs, and total drug supply days. These findings show that the access to BRAK/MEK inhibitor is increasing and as it receives indications for other malignancies, additional studies will be needed to assess whether these trends persist or change, especially in setting of increased use of immunotherapy in melanoma.
Fractionated external-beam radiation therapy in elderly patients.
Authors: Sonia Rao, Samhitha Chava, Christine Chang-Halpenny, Sukhjeet Singh Batth, Jedidiah Mercer Monson
Journal: Journal of Clinical Oncology (2024)

e13764 Background: To review the outcome of elderly patients treated with fractionated external-beam radiation therapy (RT) at a privately-owned, multi-disciplinary cancer center. Methods: From January 7, 2019, to August 22, 2023, 63 elderly patients were treated with fractionated RT at California Cancer Associates for Research and Excellence (“cCARE”), a privately-owned, multi-disciplinary cancer center in Fresno, California. The median age at the time of RT was 90 y/o (range, 85-98 y/o). Twenty-three patients were female and 40 were male. Forty-six patients identified as white and 17 as non-white. Treatment sites/histologies included primary lung 10, non-melanomatous skin 6, bone metastases 6, breast 5, esophagus 5, H&amp;N 5, prostate 4, primary CNS 3, brain metastases 3, rectum 3, bladder 2, Merkel tumor 2, sarcoma 2, anus 1, liver 1, melanoma 1, multiple myeloma 1, NHL 1, pancreas 1 and stomach 1. Results: Thirty-two of the patients (51%) were treated with curative intent. The remaining 31 patients were treated for palliation. All patients were treated with fractionated RT. However, 4 patients also received a separate course of single-fraction RT. Twenty-seven patients received more than one course of RT. The median RT course was 10 fractions (range, 1-35 fractions). Most patients had previously been treated with systemic therapy. Nearly one third (31%) received systemic therapy concurrent with their RT. The majority of the patients (73%) completed their prescribed course(s) of RT. Many patients (61%) required one or more treatment breaks. The median duration of a treatment break was 1 day (range, 1-29 days). There were no grade 3 or higher RT toxicities recorded. The median follow-up since RT was 5 months (range, 1-59 months). Twenty-four patients have expired. The mediation duration from RT to death was 5 months (range, 1-32 months ). Of the remaining 39 patients, 92% were scored as clinically stable at the time of their last f/u visit. Conclusions: In our experience at cCARE, fractionated RT was administered to elderly patients and the majority completed their prescribed treatment courses. None of the patients in our review experienced clinically significant side effects (Grade 3 or higher) during their RT even in the cohort (31%) who were treated with concurrent systemic therapy. Clearly, careful patient selection and state-of-the-art RT administration is paramount. It is also highly advantageous for patients to be treated in a multi-disciplinary setting such as cCARE where seamless coordination of cancer care among radiation oncologists, medical oncologists and surgeons excels. A companion study is in process comparing the outcome of similarly matched elderly patients from our center who were treated with systemic therapy alone. We anxiously await the outcome of this vital comparison review.
Unveiling inequities in representation: Racial disparities in supportive care breast cancer clinical trial enrollment.
Authors: Kevin R Reyes, Bryan Hill-Fung Lau, Felicia Tang, Bianca Gardner, Kathleen Cui, Evelin Trejo, Ana I. Velazquez Manana
Journal: Journal of Clinical Oncology (2024)

1605 Background: Supportive care is an integral part of breast cancer survivorship care. However, not much is known if there is adequate representation of racial minorities in supportive care breast cancer (BC) clinical trials (CTs). Methods: We conducted a systematic review of supportive care CTs for patients with BC using Covidence. A search of clinicaltrials.gov identified 2695 CTs, of which 173 met inclusion criteria. The SEER database was used as a racial distribution data reference for patients with BC. One-sample proportion tests were performed to assess adequacy in racial representation among supportive care CTs and by intervention type. Results: Of 173 supportive care CTs, 133 (77%) trials reported race-specific data. Characteristics of supportive care CTs based on intervention type and race are shown (Table). Although no statistically significant differences in frequencies of Black participants in supportive BC CTs overall were observed compared to the US population (11% vs 12%, p= 0.40), they were underrepresented in symptom management CTs specifically (8% vs 12%, p= 0.004). When stratified based on diet/physical activity CTs, Black participants were overrepresented in the study population (18% vs 11%, p= &lt;0.001). Asian participants were underrepresented in the overall study population compared to the US population (5% vs 7%, p= 0.01). However, within psycho-oncology CTs, there was an overrepresentation of Asian participants in the study population (21% vs 7%, p = &lt;0.001). No significant differences in enrollment frequencies of Black and Asian participants were found in cognitive health, complementary and alternative medicine, education/communication, and sexual health interventional CTs. Conclusions: Our findings highlight inadequate representation of Asian participants in supportive care BC CTs and Black participants in symptom management CTs. This study is limited in that ethnicity was not included in this analysis. Strategies are needed to promote recruitment of diverse individuals in these settings so that we can more accurately generalize findings from supportive care BC CTs. [Table: see text]